Список литературы

1. Siegel, R.L., et al. Cancer statistics, 2023. CA Cancer J Clin, 2023. 73: 17. https://www.ncbi.nlm.nih.gov/pubmed/36633525

2. Soria F., Shariat S.F., Lerner S.P. et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol 2017; 35(3): 379-87. DOI: 10.1007/s00345-016-1928-x.

3. Margulis V., Shariat S.F., Matin S.F. et al. Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009; 115(6): 1224-33. DOI: 10.1002/cncr.24135.

4. Shariat S.F., Favaretto R.L., Gupta A. et al. Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol 2011; 29(4): 481-6. DOI: 10.1007/s00345-010-0594-7.

5. Цуканов А.С., Кашников В.Н., Пикунов Д.Ю., Чернышов С.В. Учебно-методическое пособие: Синдром Линча. Диагностика, мониторинг и лечение; ФГБУ "НМИЦ колопроктологии им. А.Н. Рыжих" Минздрава России. - Москва: 2021. - 40 с.

6. Lonati C, Necchi A, Рисунок 25 Rivas J, Afferi L, Laukhtina E, Martini A, Ventimiglia E, Colombo R, Gandaglia G, Salonia A, Briganti A, Montorsi F, Mattei A, Simeone C, Carlo MI, Shariat SF, Spiess PE, Moschini M; European Association of Urology Young Academic Urologists EAU-YAU: Urothelial Carcinoma Working Group, the Global Society of Rare Genitourinary Tumors GSRGT. Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors. Eur Urol Oncol. 2022 Feb; 5(1): 30 - 41. DOI: 10.1016/j.euo.2021.11.001. Epub 2021 Dec 9. PMID: 34896051.

7. Lonati C, Moschini M, Simeone C, Spiess PE, Necchi A. Lynch syndrome in urological practice: diagnosis, therapeutic strategies, and screening for upper tract urothelial carcinoma. Curr Opin Urol. 2022 Jan 1; 32(1): 40 - 47. DOI: 10.1097/MOU.0000000000000936. PMID: 34608026.

8. Therkildsen C., Eriksson P., Рисунок 26 M. et al. Molecular subtype classification of urothelial carcinoma in Lynch syndrome. Mol Oncol 2018; 12(8): 1286-95. DOI: 10.1002/1878-0261.12325.

9. Colin P., Koenig P., Ouzzane A. et al. Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int 2009; 104(10): 1436-40. DOI: 10.1111/j.1464-410X.2009.08838.x.

10. Crivelli J.J., Xylinas E., Kluth L.A. et al. Effect of smoking on outcomes of urothelial carcinoma: А systematic review of the literature. Eur Urol 2014; 65(4): 742-54. DOI: 10.1016/j.eururo.2013.06.010.

11. Cosyns J.P. Aristolochic acid and "Chinese herbs nephropathy": А review of the evidence to date. Drug Saf 2003; 26(1): 33 - 48. DOI: 10.2165/00002018-200326010-00004.

12. Grollman A.P. Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease. Environ Mol Mutagen 2013; 54(1): 1 - 7. DOI: 10.1002/em.21756.

13. Rosenquist T.A., Grollman A.P. Mutational signature of aristolochic acid: Clue to the recognition of a global disease. DNA Repair (Amst) 2016; 44: 205-11. DOI: 10.1016/j.dnarep.2016.05.027.

14. Jelakovic B., Рисунок 27 S., Рисунок 28 I. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int 2012; 81(6): 559-67. DOI: 10.1038/ki.2011.371.

15. Chen C.H., Dickman K.G., Moriya M. et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci USA 2012; 109(21): 8241-6. DOI: 10.1073/pnas.1119920109.

16. Nortier J.L., Martinez M.C., Schmeiser H.H. et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000; 342(23): 1686-92. DOI: 10.1056/NEJM200006083422301.

17. Gontero, P., et al., EAU Guidelines on Non-muscle-invasive Bladder Cancer (T1, T1 and CIS), in EAU Guidelines, Edn. presented at the 40th EAU Annual Congress Madrid, 2025. https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer

18. Almas, B., et al. Higher than expected and significantly increasing incidence of upper tract urothelial carcinoma. A population based study. World J Urol, 2021. 39: 3385. https://www.ncbi.nlm.nih.gov/pubmed/33420812

19. Soria, F., et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol, 2017. 35: 379. https://www.ncbi.nlm.nih.gov/pubmed/27604375

20. Aziz, A., et al. Stage Migration for Upper Tract Urothelial Cell Carcinoma. Clin Genitourin Cancer, 2021. 19: e184. https://www.ncbi.nlm.nih.gov/pubmed/33153919

21. WHO Classification of Tumours Editorial Board. Urinary and male genital tumours. Lyon (France): International Agency for Research on Cancer; 2022. (WHO classification of tumors series, 5th ed.; vol. 8). https://publications.iarc.fr/610

22. Audenet, F., et al. Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. Clin Cancer Res, 2019. 25: 967. https://www.ncbi.nlm.nih.gov/pubmed/30352907

23. Inman B.A., Tran V.-T., Fradet Y., Lacombe L. Carcinoma of the upper urinary tract: Predictors of survival and competing causes of mortality. Cancer 2009; 115(13): 2853-62. DOI: 10.1002/cncr.24339.

24. Cowan N.C. CT urography for hematuria. Nat Rev Urol 2012; 9(4): 218-26. DOI: 10.1038/nrurol.2012.32.

25. Upper urinary tract urothelial cell carcinoma EAU Guidelines. Edn. presented at the EAU Annual Congress London 2026. ISBN 978-94-92671-32-5.

26. Ito Y., Kikuchi E., Tanaka N. et al. Preoperative hydronephrosis grade independently predicts worse pathological outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma. J Urol 2011; 185(5): 1621-6. DOI: 10.1016/j.juro.2010.12.035.

27. Raman J.D., Shariat S.F., Karakiewicz P.I. et al. Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy? Urol Oncol 2011; 29(6): 716-23. DOI: 10.1016/j.urolonc.2009.11.007.

28. The Paris System for Reporting Urinary Cytology. Eds.: E.M. Wojcik, D.F.I. Kurtycz, D.L. Rosenthal. Switzerland: Springer Nature Switzerland AG, 2022.

29. Chen A.A., Grasso M. Is there a role for FISH in the management and surveillance of patients with upper tract transitional-cell carcinoma? J Endourol 2008; 22(6): 1371-4. DOI: 10.1089/end.2008.0096.

30. Johannes, J.R., Nelson Е., Bibbo М., Bagley D.H. Voided urine fluorescence in situ hybridization testing for upper tract urothelial carcinoma surveillance. J Urol 2010; 184(3): 879-82. DOI: 10.1016/j.juro.2010.05.023.

31. Sudakoff G.S., Dunn D.P., Guralnick M.L. et al. Multidetector computerized tomography urography as the primary imaging modality for detecting urinary tract neoplasms in patients with asymptomatic hematuria. J Urol 2008; 179(3): 862-7. DOI: 10.1016/j.juro.2007.10.061.

32. Wang, L.J., Wong Y.-C., Chuang C.-K. et al. Diagnostic accuracy of transitional cell carcinoma on multidetector computerized tomography urography in patients with gross hematuria. J Urol 2009; 181(2): 524-31. DOI: 10.1016/j.juro.2008.10.024.

33. Wang L.J., Wong Y.-C., Huang C.-C. et al. Multidetector computerized tomography urography is more accurate than excretory urography for diagnosing transitional cell carcinoma of the upper urinary tract in adults with hematuria. J Urol 2010; 183: 48 - 55. DOI: 10.1016/j.juro.2009.08.144.

34. Jinzaki M., Matsumoto K., Kikuchi E. et al. Comparison of CT urography and excretory urography in the detection and localization of urothelial carcinoma of the upper urinary tract. AJR Am J Roentgenol 2011; 196(5): 1102-9. DOI: 10.2214/AJR.10.5249.

35. Hurel S., Рисунок 29 M., Seisen T. et al. Influence of preoperative factors on the oncologic outcome for upper urinary tract urothelial carcinoma after radical nephroureterectomy. World J Urol 2015; 33(3): 335-41. DOI: 10.1007/s00345-014-1311-8.

36. Verhoest G., Shariat S.F., Chromecki T.F. et al. Predictive factors of recurrence and survival of upper tract urothelial carcinomas. World J Urol 2011; 29(4): 495 - 501. DOI: 10.1007/s00345-011-0710-3.

37. David R.A., James B., Adeloye D. et al. Accuracy of ultrasound vs computed tomography scan for upper urinary tract malignancies and development of a risk-based diagnostic algorithm for haematuria in a UK tertiary centre. Int Urol Nephrol 2021 Jan; 53(1): 49 - 57. DOI: 10.1007/s11255-020-02615-7.

38. Dana A., Рисунок 30 O. Urinary tract imaging: conventional radiology and ultrasound. J Radiol 2004; 85(2 Pt 2): 159-68. (In Fr.). DOI: 10.1016/s0221-0363(04)97564-6.

39. Takahashi N., Glockner J.F., Hartman R.P. et al. Gadolinium enhanced magnetic resonance urography forupper urinary tract malignancy. J Urol 2010; 183(4): 1330-65. DOI: 10.1016/j.juro.2009.12.031.

40. Lee K.S., Zeikus E., DeWolf W.C. et al. MR urography versus retrograde pyelography/ureteroscopy for the exclusion of upper urinary tract malignancy. Clin Radiol 2010; 65(3): 185-92. DOI: 10.1016/j.crad.2009.11.003.

41. Walton T.J., Novara G., Matsumoto K. et al. Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort. BJU Int 2011; 108(3): 406-12. DOI: 10.1111/j.1464-410X.2010.09826.x.

42. Marchioni M., Primiceri G., Cindolo L. et al. Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: А systematic review and meta-analysis. BJU Int 2017; 120(3): 313-9. DOI: 10.1111/bju.13935.

43. Guo R.Q., Hong P., Xiong G.-Y. et al. Impact of ureteroscopy before radical nephroureterectomy for upper tract urothelial carcinomas on oncological outcomes: А meta-analysis. BJU Int 2018; 121(2): 184-93. DOI: 10.1111/bju.14053.

44. Bus M.T., de Bruin D.M., Faber D.J. et al. Optical diagnostics for upper urinary tract urothelial cancer: technology, thresholds, and clinical applications. J Endourol 2015; 29(2): 113-23. DOI: 10.1089/end.2014.0551.

45. Brien J.C., Shariat S.F., Herman M.P. et al. Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol 2010; 184(1): 69 - 73. DOI: 10.1016/j.juro.2010.03.030.

46. Abouassaly R., Alibhai S.M.H., Shah N. et al. Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. Urology 2010; 76(4): 895 - 901. DOI: 10.1016/j.urology.2010.04.020.

47. Kata S.G., Aboumarzouk O.M., Zreik A. et al. Photodynamic diagnostic ureterorenoscopy: A valuable tool in the detection of upper urinary tract tumour. Photodiagnosis Photodyn Ther 2016; 13: 255-60. DOI: 10.1016/j.pdpdt.2015.08.002.

48. Lindner A.K., Schachtner G., Tulchiner G. et al. Lynch syndrome: its impact on urothelial carcinoma. Int J Mol Sci 2021; 22(2): 531. DOI: 10.3390/ijms22020531.

49. Mikhaylenko D.S., Tanas A.S., Zaletaev D.V., Nemtsova M.V. Application areas of traditional molecular genetic methods and NGS in relation to hereditary urological cancer diagnosis. J Oncol 2020; 7363102. DOI: 10.1155/2020/7363102.

50. Seisen T., Peyronnet B., Dominguez-Escrig J.L. et al. Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU Nonmuscle Invasive Bladder Cancer Guidelines Panel. Eur Urol 2016; 70(6): 1052-68. DOI: 10.1016/j.eururo.2016.07.014.

51. O'Brien T., Ray E., Singh R. et al. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol 2011; 60(4): 703-10. DOI: 10.1016/j.eururo.2011.05.064.

52. Cutress, M.L., Stewart G.D., Zakikhani P. et al. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int 2012; 110(5): 614-28. DOI: 10.1111/j.1464-410X.2012.11068.x.

53. Seisen T., Granger B., Colin P. et al. A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma. Eur Urol 2015; 67(6): 1122-33. DOI: 10.1016/j.eururo.2014.11.035.

54. Cornu J.N., Рисунок 31 M., Carpentier X. et al. Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. World J Urol 2010; 28(2): 151-6. DOI: 10.1007/s00345-009-0494-x.

55. Roupret M., Traxer О., Tligui M. et al. Upper urinary tract transitional cell carcinoma: recurrence rate after percutaneous endoscopic resection. Eur Urol 2007; 51(3): 709-13; discussion 714. DOI: 10.1016/j.eururo.2006.07.019.

56. Ni S., Tao W., Chen Q. et al. Laparoscopic versus open nephroureterectomy for the treatment of upper urinary tract urothelial carcinoma: a systematic review and cumulative analysis of comparative studies. Eur Urol 2012; 61(6): 1142-53. DOI: 10.1016/j.eururo.2012.02.019.

57. Ariane M.M., Colin P., Ouzzane A. et al. Assessment of oncologic control obtained after open versus laparoscopic nephroureterectomy for upper urinary tract urothelial carcinomas (UUT-UCs): results from a large French multicenter collaborative study. Ann Surg Oncol 2012; 19(1): 301-8. DOI: 10.1245/s10434-011-1841-x.

58. Simone G., Papalia R., Guaglianone S. et al. Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomized prospective study. Eur Urol 2009; 56(3): 520-6. DOI: 10.1016/j.eururo.2009.06.013.

59. Adibi M., Youssef R., Shariat S.F. et al. Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: comparison over the three decades. Int J Urol 2012; 19(12): 1060-6. DOI: 10.1111/j.1442-2042.2012.03110.x.

60. Clements M.B., Krupski T.L., Culp S.H. Robotic-assisted surgery for upper tract urothelial carcinoma: a comparative survival analysis. Ann Surg Oncol 2018; 25(9): 2550-62. DOI: 10.1245/s10434-018-6557-8.

61. Rodriguez J.F., Packiam V.T., Boysen W.R. et al. Utilization and outcomes of nephroureterectomy for upper tract urothelial carcinoma by surgical approach. J Endourol 2017; 31(7): 661-5. DOI: 10.1089/end.2017.0086.

62. Aboumohamed A.A., Krane L.S., Hemal A.K. et al. Oncologic outcomes following robot-assisted laparoscopic nephroureterectomy with bladder cuff excision for upper tract urothelial carcinoma. J Urol 2015; 194(6): 1561-6. DOI: 10.1016/j.juro.2015.07.081.

63. Fajkovic H., Cha E.K., Jeldres C. et al. Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma. J Urol 2012; 187(3): 845-51. DOI: 10.1016/j.juro.2011.10.158.

64. Roscigno M., Brausi M., Heidenreich A. et al. Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol 2011; 60(4): 776-83. DOI: 10.1016/j.eururo.2011.07.009.

65. Lughezzani G., Jeldres C., Isbarn H. et al. A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma. Urology 2010; 75(1): 118-24. DOI: 10.1016/j.urology.2009.07.1296.

66. Moschini M., Foerster B., Abufaraj M. et al. Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy. World J Urol 2017; 35(10): 1541-7. DOI: 10.1007/s00345-017-2026-4.

67. Dominguez-Escrig J.L., Peyronnet B., Seisen T. et al. Potential benefit of lymph node dissection during radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the European Association of Urology Guidelines Panel on non-muscle-invasive bladder cancer. Eur Urol Focus 2019: 5(2): 224-41. DOI: 10.1016/j.euf.2017.09.015.

68. Kondo T., Hashimoto Y., Kobayashi H. et al. Template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract: Impact on patient survival. Int J Urol 2010; 17(10): 848-54. DOI: 10.1111/j.1442-2042.2010.02610.x.

69. Mori K. et al. Prognostic value of variant histology in upper tract urothelial carcinoma treated with nephroureterectomy: a systematic review and meta-analysis//The Journal of Urology. - 2020. - Т. 203. - N. 6. - С. 1075 - 1084.

70. Jeldres C., Lughezzani G., Sun M. et al. Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter. J Urol 2010; 183(4): 1324-9. DOI: 10.1016/j.juro.2009.12.018.

71. Colin P., Ouzzane A., Pignot G. et al. Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study. BJU Int 2012; 110(8): 1134-41. DOI: 10.1111/j.1464-410X.2012.10960.x.

72. Lopez-Beltran A., Sauter G., Gasser T. et al. Tumours of the urinary system. In: World Health Organization classification of tumors: pathology and genetics of tumours of the urinary system and male genital organs. Eds.: J.N. Eble, G. Sauter, J. Epstein, I. Sesterhenn. Lyon: IARC Press, 2004.

73. Song Y.S., Cho J.S., Cho K.S. et al. Efficacy of adjuvant gemcitabine-cisplatin chemotherapy: A comparative study between locally advanced transitional cell carcinoma of the bladder and upper urinary tract. Urol Int 2010; 85(1): 47 - 51. DOI: 10.1159/000296294.

74. TNM Classification of Malignant Tumours, 9th Edition/James D. Brierley (Editor), Meredith Giuliani (Editor), Brian O'Sullivan (Editor), Brian Rous (Editor), Elizabeth Van Eycken (Editor) ISBN: 978-1-394-21687-1

75. Downes MR, van der Kwast TH, Lopez-Beltran A, Cheng L. Grading of bladder cancer: updates, controversies and practical solutions. Histopathology. 2026 Jan; 88(1): 86 - 107. DOI: 10.1111/his.15559. PMID: 41384703; PMCID: PMC12700064

76. Paner GP, Kamat A, Netto GJ, Samaratunga H, Varma M, Bubendorf L, van der Kwast TH, Cheng L; Members of the ISUP Bladder Tumor Consensus Panel. International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 2: Grading of Mixed Grade, Invasive Urothelial Carcinoma Including Histologic Subtypes and Divergent Differentiations, and Non-Urothelial Carcinomas. Am J Surg Pathol. 2024 Jan 1; 48(1): e11 - e23. DOI: 10.1097/PAS.0000000000002077. Epub 2023 Jun 29. PMID: 37382156.

77. Yossepowitch O., Lifshitz D.A., Dekel Y. et al. Assessment of vesicoureteral reflux in patients with self-retaining ureteral stents: implications for upper urinary tract instillation. J Urol 2005; 173(3): 890-3. DOI: 10.1097/01.ju.0000147747.89028.64.

78. Матвеев В.Б., Волкова М.И., Афонин С.В., Романов В.А. ОПУХОЛИ ВЕРХНИХ МОЧЕВЫВОДЯЩИХ ПУТЕЙ: 23-ЛЕТНИЙ ОПЫТ ОДНОЙ КЛИНИКИ//Онкоурология. - 2011. - Т. 7. - N 2. - C. 39 - 45.

79. Рисунок 32 et al. Postoperative Chemotherapy Bladder Instillation After Radical Nephroureterectomy: Results of a European Survey from the Young Academic Urologist Urothelial Cancer Group European Urology Open Science Volume 22, December 2020, Pages 45 - 50.

80. Miyamoto K., Ito A., Wakabayashi M. et al. A Phase III trial of a single early intravesical instillation of pirarubicin to prevent bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403, UTUC THP Phase III). Jpn J Clin Oncol 2018; 48(1): 94-7. DOI: 10.1093/jjco/hyx158.

81. Fang D., Li X.S., Xiong G.Y. et al. Prophylactic intravesical chemotherapy to prevent bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinomas: А systematic review and meta-analysis. Urol Int 2013; 91(3): 291-6. DOI: 10.1159/000350508.

82. Foerster B., D'Andrea D., Abufaraj M. et al. Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature. Urol Oncol 2019; 37(7): 430-6. DOI: 10.1016/j.urolonc.2019.02.004.

83. Leow J.J., Martin-Doyle W., Fay A.P. et al. A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol 2014; 66(3): 529-41. DOI: 10.1016/j.eururo.2014.03.003.

84. Matin S.F., Margulis V., Kamat A. et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 2010; 116(13): 3127-34. DOI: 10.1002/cncr.25050.

85. Liao R.S., Gupta M., Schwen Z.R. et al. Comparison of pathological stage in patients treated with and without neoadjuvant chemotherapy for high risk upper tract urothelial carcinoma. J Urol 2018; 200(1): 68 - 73. DOI: 10.1016/j.juro.2017.12.054.

86. Porten S., Siefker-Radtke A.O., Xiao L. et al. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer 2014; 120(12): 1794-9. DOI: 10.1002/cncr.28655.

87. Kubota Y., Hatakeyama S., Tanaka T. et al. Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: A multicenter study. Oncotarget 2017; 8(60): 101500-8. DOI: 10.18632/oncotarget.21551.

88. Herr H.W. Extravesical tumor relapse in patients with superficial bladder tumors. J Clin Oncol 1998; 16(3): 1099-102. DOI: 10.1200/JCO.1998.16.3.1099.

89. Goldberg H., Klaassen Z., Chandrasekar T. et al. Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis. Oncotarget 2018; 9(27): 18797-810. DOI: 10.18632/oncotarget.24694.

90. Necchi A., Vullo S.L., Mariani L. et al. Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. BJU Int 2018; 121(2): 252-9. DOI: 10.1111/bju.14020.

91. Fujita K., Taneishi K., Inamoto T. et al. Adjuvant chemotherapy improves survival of patients with high-risk upper urinary tract urothelial carcinoma: a propensity score-matched analysis. BMC Urol 2017; 17(1): 110. DOI: 10.1186/s12894-017-0305-4.

92. Birtle A.J., Chester J.D., Jones R.J. et al. Results of POUT: A phase III randomized trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). J Clin Oncol 2018; 36(6 Suppl): 407. DOI: 10.1200/JCO.2018.36.6_suppl.407.

93. D.F. Bajorin, Witjes J.A., Gschwend J.E. et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 2021; 384(22): 2102-14. DOI: 10.1056/NEJMoa2034442.

94. FDA approves nivolumab for adjuvant treatment of urothelial carcinoma. Доступно по: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-adjuvant-treatment-urothelial-carcinoma (дата обращения: 17.02.2022).

95. Sharma P., Retz M., Siefker-Radtke A. et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): А multicentre, single-arm, phase 2 trial. Lancet Oncol 2017; 18(3): 312-22. DOI: 10.1016/S1470-2045(17)30065-7.

96. Czito B., Zietman А., Kaufman D. et al. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol 2004; 172(4 Pt 1): 1271-5. DOI: 10.1097/01.ju.0000137910.38441.8a.

97. Iwata T., Kimura S., Abufaraj M. et al. The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: A systematic review. Urol Oncol 2019; 37(10): 659-71. DOI: 10.1016/j.urolonc.2019.05.021.

98. Faltas B.M., Gennarelli R.L., Elkin E. et al. Metastasectomy in older adults with urothelial carcinoma: Population-based analysis of use and outcomes. Urol Oncol 2018; 36(1): 9.e11 - 17. DOI: 10.1016/j.urolonc.2017.09.009.

99. Приказ от 10 мая 2017 г. N 203н Минздрава России "Об утверждении критериев оценки качества медицинской помощи". Доступно по: https://docs.cntd.ru/document/436733768 (дата обращения: 17.02.2022).

100. Bellmunt J., de Wit R., Albanell J., Baselga J. A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. Eur J Cancer 2001; 37(17), 2212-5. DOI: 10.1016/s0959-8049(01)00295-7.

101. Bamias A., Aravantinos G., Deliveliotis C. et al. Docetaxel and cisplatin with granulocyte colonystimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: A multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 2004; 22(2): 220-8. DOI: 10.1200/JCO.2004.02.152.

102. Choueiri T.К., Jacobus S., Bellmunt J. et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: Pathologic, radiologic, and biomarker correlates. J Clin Oncol 2014; 32(18): 1889-94. DOI: 10.1200/JCO.2013.52.4785.

103. Bellmunt J, Рисунок 33 C, Demkov T, Komyakov B, Sengelov L, Daugaard G, Caty A, Carles J, Jagiello-Gruszfeld A, Karyakin O, Delgado FM, Hurteloup P, Winquist E, Morsli N, Salhi Y, Culine S, von der Maase H. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009 Sep 20; 27(27): 4454-61. DOI: 10.1200/JCO.2008.20.5534. Epub 2009 Aug 17. Erratum in: J Clin Oncol. 2010 Jan 1; 28(1): 182.

104. Balar A.V., Galsky M.D., Rosenberg J.E. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: А single-arm, multicentre, phase 2 trial. Lancet 2017; 389(10064): 67 - 76. DOI: 10.1016/S0140-6736(16)32455-2.

105. Bellmunt J., de Wit R., Vaughn D.J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017; 376(11): 1015-26. DOI: 10.1056/NEJMoa1613683.

106. Novakovic AM, Wilkins JJ, Dai H, Wade JR, Neuteboom B, Brar S, Bello CL, Girard P, Khandelwal A. Changing Body Weight-Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma. Clin Pharmacol Ther. 2020 Mar; 107(3): 588 - 596.

107. Sternberg C.N., de Mulder P.H., Schornagel J.H. et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001; 19(10): 2638-46. DOI: 10.1200/JCO.2001.19.10.2638.

108. Пембролизумаб. Инструкция к лекарственному препарату. ЛП-003972, 2021.

109. von der Maase Н., Hansen S.W., Roberts J.T. et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18(17): 3068-77. DOI: 10.1200/JCO.2000.18.17.3068.

110. Balar A.V., Castellano D., O'Donnell P.H. et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study. Lancet Oncol 2017; 18(11): 1483-92. DOI: 10.1016/S1470-2045(17)30616-2.

111. Атезолизумаб. Инструкция к лекарственному препарату. ЛП-004652-030620. Изм. N 1 к ЛП-004652-030620.

112. De Santis M., Bellmunt J., Meadet G. et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II - results of EORTC study 30986. J Clin Oncol 2009; 27(33): 5634-9. DOI: 10.1200/JCO.2008.21.4924.

113. Powles T., Park S.H., Voog E. et al. Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis. J Clin Oncol 2020; 38(18 Suppl): LBA1. DOI: 10.1200/JCO.2020.38.18_suppl.LBA1.

114. Galsky M.D., Arija J.A.A., Bamias A. et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): A multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2020; 395(10236): Р1547-57. DOI: 10.1016/S0140-6736(20)30230-0.

115. Moore M.J., Tannock I.F., Ernst D.S. et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997; 15(12): 3441-5. DOI: 10.1200/JCO.1997.15.12.3441.

116. Albers P., Siener R., Рисунок 34 M. et al. Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life. Onkologie 2002; 25(1): 47 - 52. DOI: 10.1159/000055202.

117. Sharma P., Callahan M.K., Bono P. et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): A multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 2016; 17(11): 1590-8. DOI: 10.1016/S1470-2045(16)30496-X.

118. Rosenberg J.E., Hoffman-Censits J., Powles T. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: А single-arm, multicentre, phase 2 trial. Lancet 2016; 387(10031): 1909-20. DOI: 10.1016/S0140-6736(16)00561-4.

119. Powles T., Рисунок 35 I., van der Heijden М.S. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomized controlled trial. Lancet 2018; 391(10122): 748-57. DOI: 10.1016/S0140-6736(17)33297-X.

120. Sternberg C.N., Loriot Y., James N. et al. Primary results from SAUL, a multinational ingle-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract. Eur Urol 2019; 76(1): 73 - 81. DOI: 10.1016/j.eururo.2019.03.015.

121. Hahn A.W., Giri S., Pathak R. et al. Effect of adjuvant radiotherapy on survival in patients with locoregional urothelial malignancies of the upper urinary tract. Anticancer Res 2016; 36(8): 4051-5.

122. Huang Y.C., Chang Y.-H., Chiu K.-H. et al. Adjuvant radiotherapy for locally advanced upper tract urothelial carcinoma. Sci Rep 2016; 6: 38175. DOI: 10.1038/srep38175.

123. Владимирова Л.Ю., Гладков О.А., Королева И.А. и соавт. Тошнота и рвота. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 33 - 49. https://rosoncoweb.ru/standarts/?chapter=nausea_vomiting

124. Багрова С.Г., Атрушкевич В.Г., Борзов К.А. и соавт. Патология костной ткани. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 50 - 63. https://rosoncoweb.ru/standarts/?chapter=bone_pathology

125. Сакаева Д.Д., Борисов К.Е., Булавина И.С. и соавт. Фебрильная нейтропения. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 64 - 73. https://rosoncoweb.ru/standarts/?chapter=febrile_neutropenia

126. Ткаченко П.Е., Маевская М.В., Ивашкин В.Т. Гепатотоксичность. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 2-06. https://rosoncoweb.ru/standarts/?chapter=hepatotoxicity

127. Виценя М.В., Полтавская М.Г., Потиевская В.И., Агеев Ф.Т. и соавт. Кардиоваскулярная токсичность. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 104 - 132. https://rosoncoweb.ru/standarts/?chapter=cardiovascular_toxicity

128. Королева И.А., Болотина Л.В., Гладков О.А. и соавт. Дерматологические реакции. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 133 - 175. https://rosoncoweb.ru/standarts/?chapter=dermatological_reactions

129. Громова Е.Г., Бирюкова Л.С., Курмуков И.А. и соавт. Нефротоксичность. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 199 - 217. https://rosoncoweb.ru/standarts/?chapter=nephrotoxicity

130. Сомонова О.В., Антух Э.А., Варданян А.В. и соавт. Тромбоэмболические осложнения. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 218 - 232. https://rosoncoweb.ru/standarts/?chapter=thromboembolism

131. Буйденок Ю.В., Обухова О.А. Экстравазация противоопухолевых препаратов. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 233 - 244. https://rosoncoweb.ru/standarts/?chapter=extravasation_antitumor_drugs

132. Новик А.В., Баллюзек М.Ф., Васильев Д.А. и соавт. Иммуноопосредованные нежелательные явления. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 271 - 329. https://rosoncoweb.ru/standarts/?chapter=immunerelated_adverse_events

133. Сытов А.В., Зузов С.А., Кукош М.Ю. и соавт. Нутритивная поддержка. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 176 - 185. https://rosoncoweb.ru/standarts/?chapter=nutritional_support

134. Ploussard G., Xylinas E., Lotan Y. et al. Conditional survival after radical nephroureterectomy for upper tract carcinoma. Eur Urol 2015; 67(4): 803-12. DOI: 10.1016/j.eururo.2014.08.003.

135. Stout N.L., Baima J., Swisher A.K. et al. A systematic review of exercise systematic reviews in the cancer literature (2005 - 2017). PM R. 2017; 9(9 S2): S347-84. DOI: 10.1016/j.pmrj.2017.07.074.

136. Streckmann F., Zopf E.M., Lehmann H.C. et al. Exercise intervention studies in patients with peripheral neuropathy: A systematic review. Sports Med 2014; 44(9): 1289-304. DOI: 10.1007/s40279-014-0207-5.

137. Lee M.J., Look R.M., Turner C. et al. Low-level laser therapy for chemotherapy-induced peripheral neuropathy. J Clin Oncol 2012; 30(15 Suppl): 9019. DOI: 10.1200/jco.2012.30.15_suppl.9019.

138. Rick O., von Hehn U., Mikus E. et al. Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase - III study. Bioelectromagnetics 2017; 38(2): 85 - 94. DOI: 10.1002/bem.22005.

139. Рисунок 36 M., Рисунок 37 A., Рисунок 38 S.A., Tan E. Effects of transcutaneous electrical nerve stimulation in patients with peripheral and central neuropathic pain. J Rehabil Med 2014; 46(5): 454-60. DOI: 10.2340/16501977-1271.

140. Oberoi S., Zamperlini-Netto G., Beyene J. et al. Effect of prophylactic low level laser therapy on oral mucositis: A systematic review and meta-analysis. PLoS One 2014; 9(9): e107418. DOI: 10.1371/journal.pone.0107418.

141. Ross M., Cartlidge F.E. Scalp cooling: A literature review of efficacy, safety, and tolerability for chemotherapy-induced alopecia. Clin J Oncol Nurs 2017; 21(2): 226-33. DOI: 10.1188/17.CJON.226-233.

142. Avci P., Gupta G.K., Clark J. et al. Low-level laser (light) therapy (LLLT) fortreatment of hair loss. Lasers Surg Med 2014; 46(2): 144-51. DOI: 10.1002/lsm.22170.

143. Visser W.S., Te Riele W.W., Boerma D. et al. Pelvic floor rehabilitation to improve functional outcome after a low anterior resection: А systematic review. Ann Coloproctol 2014; 30(3): 109-14. DOI: 10.3393/ac.2014.30.3.109.

144. Shigeta K., Kikuchi E., Hagiwara M. et al. The conditional survival with time of intravesical recurrence of upper tract urothelial carcinoma. J Urol 2017; 198(6): 1278-85. DOI: 10.1016/j.juro.2017.06.073.

145. Matsumoto K., Novara G., Gupta A. et al. Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: An international study. BJU Int 2011; 108(8 Pt 2): E304-9. DOI: 10.1111/j.1464-410X.2011.10188.x.

146. Singla N., Fang D., Su X. et al. A multi-institutional comparison of clinicopathological characteristics and oncologic outcomes of upper tract urothelial carcinoma in China and the United States. J Urol 2017; 197(5): 1208-13. DOI: 10.1016/j.juro.2016.11.094.

147. Simsir A., Sarsik B., Cureklibatir I. et al. Prognostic factors for upper urinary tract urothelial carcinomas: Stage, grade, and smoking status. Int Urol Nephrol 2011; 43(4): 1039-45. DOI: 10.1007/s11255-011-9915-z.

148. Rink M., Xylinas E., Margulis V. et al. Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. Eur Urol 2013; 63(6): 1082-90. DOI: 10.1016/j.eururo.2012.06.029.

149. Sundi D., Svatek R.S., Margulis V. et al. Upper tract urothelial carcinoma: Impact of time to surgery. Urol Oncol 2012; 30(3): 266-72. DOI: 10.1016/j.urolonc.2010.04.002.

150. Gadzinski A.J., Roberts W.W., Faerber G.J., Wolf J.S. Jr. Long-term outcomes of immediate versus delayed nephroureterectomy for upper tract urothelial carcinoma. J Endourol 2012; 26(5): 566-73. DOI: 10.1089/end.2011.0220.

151. Lee J.N., Kwon S.Y., Choi G.-S. et al. Impact of surgical wait time on oncologic outcomes in upper urinary tract urothelial carcinoma. J Surg Oncol 2014; 110(4): 468-75. DOI: 10.1002/jso.23589.

152. Waldert M., Karakiewicz P.I., Raman J.D. et al. A delay in radical nephroureterectomy can lead to upstaging. BJU Int 2010; 105(6): 812-7. DOI: 10.1111/j.1464-410X.2009.08821.x.

153. Favaretto R.L., Bahadori A., Mathieu R. et al. Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. World J Urol 2017; 35(1): 113-20. DOI: 10.1007/s00345-016-1835-1.

154. Scarpini S., Рисунок 39 M., Renard-Penna R. et al. Impact of the expression of Aurora-A, p53, and MIB-1 on the prognosis of urothelial carcinomas of the upper urinary tract. Urol Oncol 2012; 30(2): 182-7. DOI: 10.1016/j.urolonc.2009.12.003.

155. Roupret M., Fromont G., Azzouzi A.-R. et al. Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma. Urology 2005; 65(6): 1233-7. DOI: 10.1016/j.urology.2005.01.019.

156. Krabbe L.M., Heitplatz B., Preuss S. et al. Prognostic value of PD-1 and PD-L1 expression in patients with high grade upper tract urothelial carcinoma. J Urol 2017; 198(6): 1253-62. DOI: 10.1016/j.juro.2017.06.086.

157. Афонин С.В. Современная диагностика и лечение уротелиального рака верхних мочевых путей. Дисс.... канд. мед. наук. М. - 2010.

158. Stellato, M.; Santini, D.; Cursano, M.C.; Foderaro, S.; Tonini, G.; Procopio, G. Bone metastases from urothelial carcinoma. The dark side of the moon. J. Bone Oncol. 2021, 31, 100405.

159. O'Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: An update. World J Radiol. 2015 Aug 28; 7(8): 202-11. DOI: 10.4329/wjr.v7.i8.202. PMID: 26339464; PMCID: PMC4553252.

160. Soffietti R, Abacioglu U, Baumert B, Combs SE, Kinhult S, Kros JM, Marosi C, Metellus P, Radbruch A, Villa Freixa SS, Brada M, Carapella CM, Preusser M, Le Rhun E, Рисунок 40 R, Tonn JC, Weber DC, Weller M. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro Oncol. 2017 Feb 1; 19(2): 162 - 174.

161. Bellmunt, J., et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.NEngl J Med, 2017. 376: 1015.

162. Sideris S. et al. Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer//Molecular and Clinical Oncology. - 2016. - Т. 4. - N. 6. - С. 1063 - 1067.

163. Powles T. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomized controlled trial. Lancet 2018; 391: 748.

164. Galsky M.D. The role of taxanes in the management of bladder cancer//The oncologist. - 2005. - Т. 10. - N. 10. - С. 792 - 798.

165. McCaffrey J.A. et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma//Journal of Clinical Oncology. - 1997. - Т. 15. - N. 5. - С. 1853 - 1857.

166. Lorusso V, Pollera CF, Temi M, et al: A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Eur J Cancer 34: 1208 - 1212, 1998

167. Stadler WM, Kuzer T, Roth B, et al: A phase II trial of single agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15: 3394 - 3398, 1997.

168. Moore MJ, Tannock IF, Ernst DS, et al: Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15: 3441 - 3445, 1997.

169. Bellmunt J. et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987//Journal of Clinical Oncology. - 2012. - Т. 30. - N. 10. - С. 1107.

170. Arriola A.G.P. et al. PD-L1 expression reveals significant association with squamous differentiation in upper tract urothelial carcinoma//American Journal of Clinical Pathology. - 2019. - Т. 151. - N. 6. - С. 561 - 573.

171. Miyama Y. et al. The prognostic value of PD-L1 expression in upper tract urothelial carcinoma varies according to platelet count//Cancer medicine. - 2018. - Т. 7. - N. 9. - С. 4330 - 4338.

172. Morrissey K.M. et al. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting//Cancer chemotherapy and pharmacology. - 2019. - Т. 84. - N. 6. - С. 1257 - 1267.

173. O'Brien T. et al. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial)//European urology. - 2011. - Т. 60. - N. 4. - С. 703 - 710.

174. van Doeveren T. et al. Reduce bladder cancer recurrence in patients treated for upper urinary tract urothelial carcinoma: The REBACARE-trial//Contemporary Clinical Trials Communications. - 2018. - Т. 9. - С. 121 - 129.

175. Moriarty M.A. et al. Evaluating the safety of intraoperative instillation of intravesical chemotherapy at the time of nephroureterectomy//BMC urology. - 2015. - Т. 15. - С. 1 - 6.

176. Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Soulie M, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study. Lancet Oncol. 2024 Feb; 25(2): 255 - 264

177. Sikking C, Niggebrugge-Mentink KL, van der Sman ASE, Smit RHP, Bouman-Wammes EW, Beex-Oosterhuis MM, van Kesteren C. Hydration Methods for Cisplatin Containing Chemotherapy: A Systematic Review. Oncologist. 2024 Feb 2; 29(2): e17 - e186.

178. Li J, Wu Y, Chen C, Zhang W, Yue L, Liu T. A systematic review for prevention of cisplatin-induced nephrotoxicity using different hydration protocols and meta-analysis for magnesium hydrate supplementation. Clin Exp Nephrol. 2024 Jan; 28(1): 1 - 12.

179. Finnbladder N.B.C.S.G. et al. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial//The Lancet. - 1999. - Т. 354. - N. 9178. - С. 533 - 540.

180. Lala M., Li T.R., de Alwis D.P. et al. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. Eur. J. Canc. 2020 May; 131: 68 - 75.

181. Galsky, M.D., et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol, 2011. 12: 211.500

182. Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Soulie M, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study. Lancet Oncol. 2024 Feb; 25(2): 255 - 264

183. van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, Sade JP, Bamias A, Beuzeboc P, Bedke J, Oldenburg J, Chatta G, Рисунок 41 Y, Ye D, He Z, Valderrama BP, Ku JH, Tomita Y, Filian J, Wang L, Purcea D, Patel MY, Nasroulah F, Galsky MD; CheckMate 901 Trial Investigators. Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. N Engl J Med. 2023 Nov 9; 389(19): 1778 - 1789

184. Powles, T., et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med, 2021. 384: 1125

185. Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, Banek S, Guadalupi V, Ku JH, Valderrama BP, Tran B, Triantos S, Kean Y, Akapame S, Deprince K, Mukhopadhyay S, Stone NL, Siefker-Radtke AO; THOR Cohort 1 Investigators. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2023 Nov 23; 389(21): 1961 - 1971

186. Finnbladder N.B.C.S.G. et al. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial//The Lancet. - 1999. - Т. 354. - N. 9178. - С. 533 - 540.

187. Sideris S. et al. Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer//Molecular and Clinical Oncology. - 2016. - Т. 4. - N. 6. - С. 1063 - 1067.

188. Albany C., Sonpavde G. Docetaxel for the treatment of bladder cancer//Expert opinion on investigational drugs. - 2015. - Т. 24. - N. 12. - С. 1657 - 1664.

189. Galsky MD, Chen GJ, Oh WK, Bellmunt J, Roth BJ, Petrioli R, Dogliotti L, Dreicer R, Sonpavde G. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol. 2012 Feb; 23(2): 406-10.

190. Sonpavde GP, Mariani L, Lo Vullo S, Raggi D, Giannatempo P, Bamias A, Crabb SJ, Bellmunt J, Yu EY, Niegisch G, Vaishampayan UN, Theodore C, Berthold DR, Srinivas S, Sridhar SS, Plimack ER, Rosenberg JE, Powles T, Galsky MD, Necchi A. Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. J Urol. 2018 Dec; 200(6): 1207 - 1214.

191. Rosiello, G., et al. Contemporary conditional cancer-specific survival after radical nephroureterectomy in patients with nonmetastatic urothelial carcinoma of upper urinary tract. J Surg Oncol, 2020. 121: 1154

192. Zamboni, S., et al. Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy. BJU Int, 2019. 124: 738.

193. Yu, J., et al. Impact of squamous differentiation on intravesical recurrence and prognosis of patients with upper tract urothelial carcinoma. Ann Transl Med, 2019. 7: 377.

194. Krajewski, W., et al. Impact of Histological Subtypes/Divergent Differentiation on Clinicopathological and Oncological Outcomes for Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy: A Comprehensive Updated Systematic Review and Meta-analysis. Eur Urol Oncol, 2025. 8: 1126.

195. Janisch, F., et al. Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis. World J Urol, 2020. 38: 1165.

196. Messer, J.C., et al. Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. Urol Oncol, 2013. 31: 904.

197. Ito, Y., et al. Preoperative hydronephrosis grade independently predicts worse pathological outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma. J Urol, 2011. 185: 1621.

198. Ye, T., et al. Prognostic Value of Preoperative Hydronephrosis in Patients Undergoing Radical Nephroureterectomy for Upper Tract Urinary Carcinoma: A Systematic Review and Meta-Analysis. Front Oncol, 2020. 10: 600511.

199. Ma, R., et al. Prognostic Value of Tumor Size in Patients with Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-analysis. Eur Urol Open Sci, 2022. 42: 19.

200. Foerster, B., et al. The Performance of Tumor Size as Risk Stratification Parameter in Upper Tract Urothelial Carcinoma (UTUC). Clin Genitourin Cancer, 2021. 19: 272 e1.

201. Slusarczyk, A., et al. Oncologic outcomes of patients treated with kidney-sparing surgery or radical nephroureterectomy for upper urinary tract urothelial cancer: a population-based study. Urol Oncol, 2024. 42: 22 e1.

202. Kawada, T., et al. Oncologic and Safety Outcomes for Endoscopic Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An Updated Systematic Review and Meta-analysis. Eur Urol Focus, 2023. 9: 236.

203. Gallioli, A., et al. Oncologic Outcomes of Endoscopic Management of Upper Tract Urothelial Carcinoma: A Systematic Review and Pooled Analysis from the EAU-YAU Urothelial Working Group. Eur Urol Focus, 2025.

204. Vemana, G., et al. Survival Comparison Between Endoscopic and Surgical Management for Patients With Upper Tract Urothelial Cancer: A Matched Propensity Score Analysis Using Surveillance, Epidemiology and End Results-Medicare Data. Urology, 2016. 95: 115.

205. Villa, L., et al. Early repeated ureteroscopy within 6 - 8 weeks after a primary endoscopic treatment in patients with upper tract urothelial cell carcinoma: preliminary findings. World J Urol, 2016. 34: 1201.

206. Abrate, A., et al. Segmental Ureterectomy Versus Radical Nephroureterectomy in Older Patients Treated for Upper Tract Urothelial Carcinoma. Clin Genitourin Cancer, 2022. 20: 381.

207. Rajan, K., et al. Oncological Efficacy of Robotic Nephroureterectomy vs. Open and Laparoscopic Nephroureterectomy for Suspected Non-Metastatic UTUC-A Systematic Review and Meta-Analysis. Cancers (Basel), 2023. 15(20): 4926

208. Veccia, A., et al. Robotic vs Laparoscopic Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Propensity-Score Matched Pair "tetrafecta" Analysis (ROBUUST Collaborative Group). J Endourol, 2022. 36: 752.

209. Zhu, P.Y., et al. Perioperative and oncologic outcomes of transperitoneal versus retroperitoneal laparoscopic nephroureterectomy for upper urinary tract urothelial carcinoma: a systematic review and pooled analysis of comparative outcomes. World J Surg Oncol, 2023. 21: 163.

210. Ji, R., et al. Robot-assisted vs. laparoscopic nephroureterectomy for upper urinary tract urothelial carcinoma: a systematic review and meta-analysis based on comparative studies. Front Oncol, 2022. 12: 964256

211. Xylinas, E., et al. Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool. Eur Urol, 2014. 65: 650.

212. Dong, F., et al. Lymph node dissection could bring survival benefits to patients diagnosed with clinically node-negative upper urinary tract urothelial cancer: a population-based, propensity score-matched study. Int J Clin Oncol, 2019. 24: 296.

213. Lenis, A.T., et al. Role of surgical approach on lymph node dissection yield and survival in patients with upper tract urothelial carcinoma. Urol Oncol, 2018. 36: 9 e1.

214. Said MA, Warner H, Stout TE, Harrison R, Loeffler B, Stifelman MD, Packiam VT, Tracy CR, Gellhaus PT. Immediate gemcitabine bladder instillation following bladder closure during robotic-assisted radical nephroureterectomy: a multi-institutional report of feasibility and initial outcomes. Transl Androl Urol. 2023 Aug 31; 12(8): 1229 - 1237.

215. Ali Deb, A., et al. Role of Neoadjuvant Chemotherapy on Pathological, Functional, and Survival Outcomes of Upper Tract Urothelial Carcinoma Patients: A Systematic Review and Meta-Analysis. Urol Res Pract, 2024. 50: 13.

216. Necchi, A., et al. A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02. Urol Oncol, 2022. 40: 10 e1.

217. Houede, N., et al. Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 Trial. J Clin Oncol, 2025. 43: 1578.

218. Holmsten K, Omland LH, Als AB, Рисунок 42 M, Dohn LH, Lindberg H, Jensen NV, Carus A, Moe M, Hosseini A, Radkiewicz C, Pappot H, Рисунок 43 A. Implications for Efficacy and Safety of Total Dose and Dose-Intensity of Neoadjuvant Gemcitabine-Cisplatin in Muscle-Invasive Bladder Cancer: Three-Week Versus Four-Week Regimen. Bladder Cancer. 2022 Mar 11; 8(1): 71 - 80.

219. O'Dwyer R, Musat MG, Gulas I, Hubscher E, Moradian H, Guenther S, Kearney M, Sridhar SS. Split-Dose Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Systematic Literature Review and Network Meta-Analysis. Clin Genitourin Cancer. 2024 Dec; 22(6): 102176. DOI: 10.1016/j.clgc.2024.102176. Epub 2024 Jul 25. PMID: 39260094.

220. Wong RL, Ferris LA, Do OA, Holt SK, Ramos JD, Crabb SJ, Sternberg CN, Bellmunt J, Ladoire S, De Giorgi U, Harshman LC, Vaishampayan UN, Necchi A, Srinivas S, Pal SK, Niegisch G, Dorff TB, Galsky MD, Yu EY. Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease. Oncologist. 2021 Dec; 26(12): 1026 - 1034.

221. Carmichael J. The role of gemcitabine in the treatment of other tumours//British Journal of Cancer. - 1998. - Т. 78. - N. 3. - С. 21 - 25.

222. Pollera CF, Ceribelli A, Crecco M, et al: Weekly gemcitabine in advanced bladder cancer: A preliminary report of a phase I study. Ann Oncol 5: 182 - 184, 1994.

223. Lorusso V, Pollera CF, Temi M, et al: A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Eur J Cancer 34: 1208 - 1212, 1998.

224. Stadler WM, Kuzer T, Roth B, et al: A phase II trial of single agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15: 3394 - 3398, 1997.

225. Moore MJ, Tannock IF, Ernst DS, et al: Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15: 3441 - 3445, 1997.

226. Yu, E.Y., et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. Lancet Oncol, 2021. 22: 872 - 882

227. Farag CM, Antar R, Akosman S, Ng M, Whalen MJ. What is hemoglobin, albumin, lymphocyte, platelet (HALP) score? A comprehensive literature review of HALP's prognostic ability in different cancer types. Oncotarget. 2023 Feb 25; 14: 153 - 172. DOI: 10.18632/oncotarget.28367.

228. Xia L, Guzzo TJ. Preoperative Anemia and Low Hemoglobin Level Are Associated With Worse Clinical Outcomes in Patients With Bladder Cancer Undergoing Radical Cystectomy: A Meta-Analysis. Clin Genitourin Cancer. 2017 Apr; 15(2): 263 - 272. e4. DOI: 10.1016/j.clgc.2016.08.017. Epub 2016 Aug 29. PMID: 27665259.

229. Hackemer P, Рисунок 44 B, Menzel F, Drabik A, Tupikowski K, Zdrojowy R. Determinants of survival in patients with bladder cancer undergoing radical cystectomy: The impact of serum creatinine level. Adv Clin Exp Med. 2021 Jan; 30(1): 77 - 82. DOI: 10.17219/acem/130597.

230. Wu J, Chen L, Wang Y, Tan W, Huang Z. Prognostic value of aspartate transaminase to alanine transaminase (De Ritis) ratio in solid tumors: a pooled analysis of 9,400 patients. Onco Targets Ther. 2019 Jul 2; 12: 5201 - 5213. DOI: 10.2147/OTT.S204403. eCollection 2019.

231. Zareba P, Duivenvoorden WCM, Pinthus JH. Thromboembolism in Patients with Bladder Cancer: Incidence, Risk Factors and Prevention. Bladder Cancer. 2018 Apr 26; 4(2): 139 - 147. DOI: 10.3233/BLC-170146.

232. Azuma T, Nagase Y, Oshi M. Pyuria predicts poor prognosis in patients with non-muscle-invasive bladder cancer. Clin Genitourin Cancer. 2013 Sep; 11(3): 331-6. DOI: 10.1016/j.clgc.2013.04.002. Epub 2013 May 9.

233. Yafi F.A. et al. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol 2015. 33: 66. e25.

234. Tetu B. Diagnosis of urothelial carcinoma from urine. Mod Pathol 2009. 22 Suppl 2: S53.

235. Raitanen M.P. et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol 2002. 41: 284.

236. Karakiewicz P.I. et al. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int 2006. 97: 997.

237. Soria F. et al. An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. World J Urol 36: 1981.

238. Mansinho A, Machado JC, Faustino C, Figueiredo A, Moreira Pinto J, Vau N, Ramalho-Carvalho J, Teixeira MR. FGFR Testing in Metastatic Urothelial Carcinoma-Who, When, and How to Test. Cancers (Basel). 2026 Jan 29; 18(3): 444. DOI: 10.3390/cancers18030444. PMID: 41681916; PMCID: PMC12896470.

239. Mazzaschi G, Giudice GC, Рисунок 45 M, Campobasso D, Perrone F, Maffezzoli M, Testi I, Isella L, Maestroni U, Buti S. Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario. Technol Cancer Res Treat. 2023 Jan-Dec; 22: 15330338231159753. DOI: 10.1177/15330338231159753. PMID: 36855829; PMCID: PMC9983117

240. Song Y, Jiang S, Peng Y, Du Y, Qin C, Xu T. FGFR3 alteration sites and response rate to FGFR inhibitors in urothelial carcinoma. Pharmacol Res. 2025 Nov; 221: 107968. DOI: 10.1016/j.phrs.2025.107968. Epub 2025 Sep 24. PMID: 41005586

241. Guercio BJ, Sarfaty M, Teo MY, Ratna N, Duzgol C, Funt SA, Lee CH, Aggen DH, Regazzi AM, Chen Z, Lattanzi M, Al-Ahmadie HA, Brannon AR, Shah R, Chu C, Lenis AT, Pietzak E, Bochner BH, Berger MF, Solit DB, Rosenberg JE, Bajorin DF, Iyer G. Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience. Clin Cancer Res. 2023 Nov 14; 29(22): 4586 - 4595. DOI: 10.1158/1078-0432.CCR-23-1283. PMID: 37682528; PMCID: PMC11233068

242. Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones CL, Wolff DJ, Younes A, Nikiforova MN. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017 Jan; 19(1): 4 - 23. DOI: 10.1016/j.jmoldx.2016.10.002. PMID: 27993330; PMCID: PMC5707196

243. Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O'Hagan A, Avadhani A, Siefker-Radtke AO; BLC2001 Study Group. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2019 Jul 25; 381(4): 338 - 348.

244. Nacional Comprehensive Cancer Network Guidelines. Bladder Cancer. Version 3.2025

245. Somoto T, Utsumi T, Ikeda R, Ishitsuka N, Noro T, Suzuki Y, Iijima S, Sugizaki Y, Oka R, Endo T, Kamiya N, Suzuki H. Precision Care for Hereditary Urologic Cancers: Genetic Testing, Counseling, Surveillance, and Therapeutic Implications. Curr Oncol. 2025 Dec 11; 32(12): 698. DOI: 10.3390/curroncol32120698. PMID: 41440226; PMCID: PMC12731482

246. Рисунок 46 ML, Kenessey I, Kiss A, Barbai T, Kulka J, Рисунок 47 E, Рисунок 48 J. Comparison of standard mismatch repair deficiency and microsatellite instability tests in a large cancer series. J Transl Med. 2024 Feb 13; 22(1): 150. DOI: 10.1186/s12967-024-04960-y. PMID: 38350968; PMCID: PMC10863158], [Kwak Y, Bae JM, Lee HS. Diagnostic Challenges and Clinical Implications of Microsatellite Instability/Mismatch Repair Deficiency in Solid Tumors. Cancer Res Treat. 2026 Jan; 58(1): 1 - 14. DOI: 10.4143/crt.2025.1161. Epub 2025 Dec 26. PMID: 41472355; PMCID: PMC12813303

247. ACR Appropriateness Рисунок 49. Pretreatment staging of Upper urinary tract urothelial cancer/American College of Radiology. - 2024. - URL: https://acsearch.acr.org/list.

248. Cowan, N.C. CT urography for hematuria/N.C. Cowan//Nature Reviews Urology. - 2012. - Vol. 9, N 4. - P. 218 - 226.

249. Takahashi, N. MR urography for suspected upper tract urothelial carcinoma/N. Takahashi, A. Kawashima, J.F. Glockner [et al.]//European Radiology. - 2009. - Vol. 19, N 4. - P. 912 - 923.

250. Sean A. Woolen, MD, MS. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent. A Systematic Review and Meta-analysis. Sean A. Woolen, MD, MS, JAMA Intern Med Published Online: December 9, 2019 - 2020; 180; (2): 223 - 230.

251. Voskuilen, C.S. Diagnostic value of 18F-fluorodeoxyglucose positron emission tomography with computed tomography for lymph node staging in patients with upper tract urothelial carcinoma/C.S. Voskuilen, D. Schweitzer, J.B. Jensen [et al.]//European Urology Oncology. - 2020. - Vol. 3, N 1. - P. 73 - 79.

252. Рыжкова О.П., Кардымон О.Л., Прохорчук Е.Б., Коновалов Ф.А., Масленников А.Б., Степанов В.А., Афанасьев А.А., Заклязьминская Е.В., Ребриков Д.В., Савостьянов К.В., Глотов А.С., Костарева А.А., Павлов А.Е., Голубенко М.В., Поляков А.В., Куцев С.И. Руководство по интерпретации данных последовательности ДНК человека, полученных методами массового параллельного секвенирования (MPS) (редакция 2018, версия 2). Медицинская генетика. 2019; 18(2): 3 - 23. DOI: 10.25557/2073-7998.2019.02.3-23

253. Coleman JA, Yip W, Wong NC, et al. Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma. J Clin Oncol. 2023 Mar 10; 41(8): 1618 - 1625.

254. Kari M. etal. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. Cancer Chemother Pharmacol. 2019; 84(6): 1257 - 1267.

255. Клинические рекомендации по профилактике и лечению осложнений злокачественных опухолей и противоопухолевой лекарственной терапии Российского общества клинической онкологии. https://www.rosoncoweb.ru/standarts/suptherapy

256. Клинические рекомендации "Анемия при злокачественных новообразованиях" (ID: КР624, год утверждения 2024) https://cr.minzdrav.gov.ru/view-cr/624_2

257. Семиглазова Т.Ю., Беляк Н.П., Владимирова Л.Ю. и соавт. Мукозиты. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 352 - 364. https://rosoncoweb.ru/standarts/?chapter=mucositis

258. Орлова Р.В., Гладков О.А., Кутукова С.И. и соавт. Анемия. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 23 - 32. https://rosoncoweb.ru/standarts/?chapter=anemia

259. Сытов А.В., Зузов С.А., Кукош М.Ю. и соавт. Синдром анорексии-кахексии. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 186 - 192. https://rosoncoweb.ru/standarts/?chapter=anorexia-cachexia

260. Исянгулова А.З., Шин А.Р., Петкау В.В. Центральный венозный доступ. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 387 - 400. https://rosoncoweb.ru/standarts/?chapter=central_venous_access

261. Когония Л.М., Новиков Г.А., Орлова Р.В. и соавт. Хронический болевой синдром у взрослых онкологических больных. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 245 - 270. https://rosoncoweb.ru/standarts/?chapter=chronic_pain_syndrome

262. Орлова Р.В., Жабина А.С., Иванова А.К. и соавт. Инфузионные реакции. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 365 - 386. https://rosoncoweb.ru/standarts/?chapter=infusion_reactions

263. Феоктистова П.С., Винницкая Е.В., Нурмухаметова Е.А., Тихонов И.Н. Реактивация/обострение хронических вирусных гепатитов во время противоопухолевой терапии. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 401 - 409. https://rosoncoweb.ru/standarts/?chapter=chronic_viral_hepatitis

264. Латипова Д.Х., Андреев В.В., Маслова Д.А. и соавт. Неврологические осложнения. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 410 - 425. https://rosoncoweb.ru/standarts/?chapter=neurological_complication

265. De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Gil T, Marreaud S, Daugaard G, Skoneczna I, Collette S, Lorent J, de Wit R, Sylvester R. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012 Jan 10; 30(2): 191-9.

266. Cappuzzo F, Zvirbule Z, Korbenfeld E, Kolb-Sielecki J, Isla D, Szczesna A, Castro Sanchez AY, Bustillos A, Liu X, Young F, Tosti N, Monteiro MF, Majem M. Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC. JTO Clin Res Rep. 2025 Feb 19; 6(5): 100815.

267. Long GV, Tykodi SS, Schneider JG, Garbe C, Gravis G, Rashford M, Agrawal S, Grigoryeva E, Bello A, Roy A, Rollin L, Zhao X. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Ann Oncol. 2018 Nov 1; 29(11): 2208 - 2213.

268. Рисунок 50 J, Krajewski W, Рисунок 51 A, Nowak Рисунок 52, Рисунок 53 J, Subiela JD, Tomczak W, Del Giudice F, Рисунок 54 B, Рисунок 55 T. Blood-, Tissue- and Urine-Based Prognostic Biomarkers of Upper Tract Urothelial Carcinoma. Diagnostics (Basel). 2024 Aug 31; 14(17): 1927.

269. Mahyoub MA, Yousef BM, Ghaleb RAM, Obad S, Mothanna A, Al-Yousofy F, Elhoumed M, Abbas M, Alnaggar M, Ren M, He S. Vesicoureteral reflux postoperative radical nephroureterectomy for upper urinary tract urothelial carcinoma: A case report. Heliyon. 2024 Apr 26; 10(9): e30294.

270. Fikri J, Almalki AM, Almalki SA, Murad M, Makhdoum S, Hassan F. Upper Urinary Tract Urothelial Carcinoma With Squamous, Glandular, and Sarcomatoid Variants in a Horseshoe Kidney: A Novel Case Report and Literature Review. Cureus. 2021 Nov 16; 13(11): e19627.

271. Asao K, McHugh JB, Miller DC, Esfandiari NH. Hypercalcemia in upper urinary tract urothelial carcinoma: a case report and literature review. Case Rep Endocrinol. 2013; 2013: 470890.

272. A. Sahgal, S.D. Myrehaug, S. Siva et al. Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial. Lancet Oncol. 2021 Jul; 22(7): 1023 - 1033.

273. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 2011; 9(5): 188-95

274. Piechotta V, Adams A, Haque M, et al. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis. Cochrane Database Syst Rev 2021; 11(11): CD012775

275. Chen C, Li R, Yang T. Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials. Clinical Therapeutics 2020; 42(8): 1494-1507.e1

276. Krishan S, Panditaratne N, Verma R, Robertson R. Incremental value of CT venography combined with pulmonary CT angiography for the detection of thromboembolic disease: systematic review and meta-analysis. AJR Am J Roentgenol 2011; 196(5): 1065-72.

277. Samaranayake CB, Anderson J, McCabe C, et al. Direct oral anticoagulants for cancer-associated venous thromboembolisms: a systematic review and network meta-analysis, Intern Med J 2022; 52(2): 272 - 281.

278. Knoll W, Fergusson N., Ivankovic V, et al. Extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: A systematic review and meta-analysis of the literature, Thromb Res 2021; 204: 114 - 122.

279. NCCN Guidelines. Prevention and Treatment of Cancer-Related Infections. v.1, 2021. https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf.

280. Kosaka Y, Rai Y, Masuda N, et al. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Support Care Cancer 2015; 23(4): 1137-43.

281. Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy 2006; 57(2): 176 - 189.

282. Vincenzi B, Russo A, Terenzio A, et al. The use of SAMe in chemotherapy-induced liver injury. Crit Rev Oncol Hematol 2018; 130: 70 - 77.

283. Remash D, Prince DS, McKenzie C, et al. Immune checkpoint inhibitor-related hepatotoxicity: A review. World J Gastroenterol 2021; 27(32): 5376 - 5391.

284. Mao Z, Shen K, Zhu L, et al. Comparisons of Cardiotoxicity and Efficacy of Anthracycline-Based Therapies in Breast Cancer: A Network Meta-Analysis of Randomized Clinical Trials. Oncol Res Treat 2019; 42(7 - 8): 405 - 413.

285. Albakri A. Systolic heart failure: A review of clinical status and metaanalysis of diagnosis and clinical management methods. Trends in Res 2018; 1(4).

286. Tromp J, Ouwerkerk W, van Veldhuisen DJ, et al. A Systematic Review and Network-Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. JACC Heart Fail 2022 Feb; 10(2): 73 - 84.

287. Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis. Eur J Cancer 2013; 49(13): 2900-9.

288. Li J, Yan H. Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of 65 randomized controlled trials. Cancer Chemother Pharmacol 2018; 82(4): 571 - 583.

289. Martin EJ, Bruggeman AR, Nalawade VV, et al. Palliative Radiotherapy Versus Esophageal Stent Placement in the Management of Patients With Metastatic Esophageal Cancer. J Natl Compr Canc Netw 2020; 18(5): 569 - 574.

290. de van der Schueren MAE, Laviano A, Blanchard H, et al. Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy: current evidence and guidance for design of future trials. Ann Onc Perazella MA. Onco-Nephrology. Renal Toxicities of Chemotherapeutic Agents.

291. Clinical Journal of the American Society of Nephrology 2012; 7(10): 1713 - 1721. ol 2018; 29(5): 1141 - 1153.

292. Li H, Xu J, Bai Y, et al. Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis. Investigational New Drugs 2021; 39: 860 - 870.

293. Li S, He X, Ruan L, et al. Protective Effect of Mannitol on Cisplatin-Induced Nephrotoxicity: A Systematic Review and Meta-Analysis. Front Oncol 2021; 11: 804685

294. NCCN guidelines. Management of Immunotherapy-Related Toxicities. Version 4, 2021. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf.

295. Johnson DH, Zobniw CM, Trinh VA, et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 2018; 6(1): 103.

296. De Velasco G, Je Y, Рисунок 56 D, et al. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res 2017; 5(4): 312 - 318

297. Zhang H, Li X, Huang X, et al. Impact of corticosteroid use on outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Journal of Clinical Pharmacy and Therapeutics 2021; 46(4): 927 - 935

298. Bossi P, Antonuzzo A., Cherny NI, et al. Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2018; 29(4): iv126 - iv142.

299. Peterson DE, Bensadoun RJ, Roila F. Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Ann Oncol 2010; 21 (Suppl 5): v261 - v265.

300. Ohashi Y, Uemura Y, Fujisaka Y, et al. Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. Cancer Sci 2013; 104(4): 481-5.

301. Gafter-Gvili A, Rozen-Zvi B, Vidal L, et al. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia - systematic review and meta-analysis of randomised controlled trials. Acta Oncol 2013; 52(1): 18 - 29.

302. Zhang F, Shen A, Jin Y, Qiang W. The management strategies of cancer-associated anorexia: a critical appraisal of systematic reviews. BMC Complement Altern Med 2018; 18: 236.

303. Kreidieh FY, Moukadem HA, El Saghir NS. Overview, prevention and management of chemotherapy extravasation. World J Clin Oncol 2016; 7(1): 87 - 97.

304. Evenepoel M, Haenen V, De Baerdemaecker T, et al. Pain Prevalence During Cancer Treatment: A Systematic Review and Meta-Analysis. Pain Symptom Manage 2022; 63(3): e317 - e335

305. Rosello S, Blasco I, Fabregat LG, et al. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. Ann Oncol 2017; 28 (Suppl 4): iv100 - iv118.

306. Mustafayev K, Torres H. Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies. Clin Microbiol Infect 2022; 28(10): 1321 - 1327.

307. Alberti P, Salvalaggio A, Argyriou AA, et al. Neurological Complications of Conventional and Novel Anticancer Treatments. Cancers (Basel) 2022; 14(24): 6088.